Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase
Drug Metabolism and Disposition · 2026-04 · 54 (4) · 100274
DOI: 10.1016/j.dmd.2026.100274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-04. Verfasst von Qianqian Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, Chi…. Hauptthemen laut MEDLINE: Fluorouracil, Stomach Neoplasms, Pyrimidines, Cyclopentanes. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
The therapeutic efficacy of 5-fluorouracil (5-FU), a cornerstone of gastric cancer chemotherapy, is predominantly limited by its catabolic inactivation in tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme responsible for 5-FU inactivation, and its tumor-specific overexpression constitutes a primary mechanism of 5-FU resistance. Here, we report a novel strategy to increase the sensitivity of 5-FU by targeting the post-translational regulation of DPD. We demonstrate that the neural precursor cell expressed, developmentally downregulated 8-activating enzyme (NAE) inhibitor MLN4924 significantly enhances the antitumor activity of 5-FU in both cellular and animal models of gastric cancer without augmenting systemic toxicity. Mechanistically, MLN4924 treatment inhibits the neddylation of DPD, which is dependent on the NAE1/ubiquitin-conjugating enzyme 12 axis. This inhibition triggers the ubiquitination and subsequent proteasomal degradation of DPD, thereby reducing intracellular 5-FU catabolism and augmenting its cytotoxic effects. Our findings identify neddylation as a previously unrecognized regulatory mechanism governing DPD protein stability and activity. This work identifies the neddylation-DPD axis as a novel therapeutic target and provides a strong rationale for combining NAE inhibition with 5-FU-based chemotherapy in gastric cancer. SIGNIFICANCE STATEMENT: This study establishes neddylation as a previously unrecognized regulatory mechanism that stabilizes the drug-metabolizing enzyme dihydropyrimidine dehydrogenase to drive 5-fluorouracil resistance in gastric cancer. It further unveils that inhibiting neddylation with MLN4924 selectively depletes tumor dihydropyrimidine dehydrogenase, enhancing chemotherapy efficacy without increasing toxicity, thereby proposing a targeted strategy to overcome chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China.
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China; Department of Pharmacy, Nanshi Hospital of Nanyang, Nanyang, China.
- School of Pharmaceutical Sciences & Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education, Zhengzhou University, Zhengzhou, China. Electronic address: fsq1212@zzu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Zhang, Q., Hu, J., Liu, Y., Xie, D., Bai, L., Hu, Z., Tang, Y., & Feng, S. (2026). Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase. Drug Metabolism and Disposition, 54(4), 100274. https://doi.org/10.1016/j.dmd.2026.100274
Vancouver
Zhang Q, Hu J, Liu Y, Xie D, Bai L, Hu Z, et al. Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase. Drug Metabolism and Disposition. 2026;54(4):100274. doi:10.1016/j.dmd.2026.100274
BibTeX
@article{Zhang2026,
author = {Zhang, Qianqian and Hu, Jingyi and Liu, Yangbo and Xie, Dongzhao and Bai, Linyue and Hu, Zhuang and Tang, Yanjun and Feng, Siqi},
title = {Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {4},
pages = {100274},
doi = {10.1016/j.dmd.2026.100274}
}
EUVIMED